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Background. Use of antiretroviral therapy (ART) may be associated with higher pregnancy rates. Methods. The prevalence and
incidence of pregnancy was assessed in 712 HIV+ pre-ART women of reproductive age (WRA) (15–45) and 244 HIV+ WRA
initiating ART. Prevalence rate ratios (PRR), incidence rate ratios (IRR), and 95% conﬁdence interval (CI) were assessed. Results.
The incidence of pregnancy was 13.1/100 py among women in pre-ART care compared to 24.6/100 py among women on ART
(IRR = 0.54; 95% CI 0.37, 0.81, p<0.0017). The prevalence of pregnancy at ART initiation was 12.0% with CD4 counts 100–250
compared with 3.2% with CD4 <100 (PRR = 3.24, CI 1.51–6.93), and the incidence of pregnancy while on ART was highest in
women with a good immunologic response. Desire for more children was a very important factor in fertility. Conclusion.A R Tw a s
associated with increased pregnancy rates in HIV+ women, particularly those with higher CD4 counts and good immunologic
response to therapy, suggesting a need to strengthen reproductive health services for both women and their partners that could
address their fertility decisions/intentions particularly after ART initiation.
1.Introduction
The HIV/AIDs epidemic remains a serious public health
challenge, as well as a social dilemma especially among
women of childbearing age [1] who were 46% of the
HIV global burden [2]. HIV infected women face diﬃ-
cult decisions regarding childbearing. HIV-infection com-
promises their immunity which further aggravates their
chances of conception as well as sustaining a pregnancy
to term. Reduced fertility among HIV-positive women has
been reported in sub-Saharan Africa [3–7]. Fertility is not
impaired during early HIV infection [8, 9] but declines with
disease progression, and the reduction is greatest with onset
of AIDS [10]. The mechanisms through which fertility rates
are reduced by HIV are not fullyunderstood, but higher viral
load and decreased CD4 counts with advanced HIV disease
are likely to be implicated [11]. Also, progression to AIDS
leads to decreased general health and well-being that may be
associated with reduced sexual activity. However, the advent
of ART has improved the general health and may increase
sexualactivity,andimprovedsurvivalprospectsmayincrease
the desire for more children [12–15]. Desire for more
children may also be due to improvements in pregnancy
care that have reduced the risk of vertical transmission,
especially if pregnant women receive timely ART or if they
deliver by caesarean section and avoid breastfeeding when
recommended. However, even in the era of HIV/AIDS other
predictors of fertility including age, marital status, level of
education, and socioeconomic status still play a signiﬁcant
role in determining fertility [16–20]. A combination of all
these factors may be associated with the currently observed
increase in pregnancy rates among women on ART [21, 22].
Although HIV-infected women’s fertility desires have been
studied, there is limited information on the possible role2 AIDS Research and Treatment
of the improving immunological and virological outcomes
on the actual fertility among women initiated on ART.
Understanding the eﬀects of ART on women’s fertility is
critically important for health service providers to be able
to protect the reproductive rights of HIV-infected women
through creating increased access to sexual and reproductive
health services and sexuality education, so that women may
decide freely and responsibly on their family size through
spacing and timing of their pregnancies [23] In this paper we
therefore assess the association between HIV infection, ART
use,andpregnancyrates,takingintoaccountimmunological
and virological status, in a community-based HIV care
program in Rakai district, Uganda.
2. Methods
2.1. Study Setting, Population, and HIV Treatment and
Care. Since June 2004, with funding from the President’s
EmergencyPlanForAIDSRelief(PEPFAR),theRakaiHealth
Sciences Program (RHSP) in Uganda has oﬀered HIV care
and ART free of charge. HIV care, oﬀered to all HIV-infected
persons, includes cotrimoxazole prophylaxis, treatment for
opportunistic infections, reproductive health services, treat-
mentofopportunisticinfections,cotrimoxazoleprophylaxis,
provision of a basic care package, health education, and HIV
counseling. Individuals are initiated on ART at a CD4 cell
count ≤250 cells/mm3 or WHO Stage IV disease. General
HIV care and ART is provided via 17 mobile community-
based out-patient clinics, called Suubi or “Hope” clinics.
All patients are oﬀered ongoing HIV counseling, health
education including family planning, prevention of mother
to child transmission of HIV, and counseling on reduction of
risky sexual behaviors for example, multiple sexual partners.
At each visit, general health status is evaluated, and use of
family planning methods are ascertained.
At the time data were collected for these analyses,
individuals on HIV care but not yet started on ART were
seen every 3 to 6 months depending on CD4 cell count.
Patients initiating ART were followed weekly for the ﬁrst
month, biweekly for the subsequent 2 months, monthly
until one year on treatment, and then every 2 months
thereafter. CD4 counts were assessed every 3 or 6 months
prior to ART, at time of ART initiation, and every 3 months
thereafter. Viral load was tested at time of ART initiation
and then at 6 monthly intervals. Two weeks prior to ART
initiation, women were interviewed regarding their and their
sexual partner’s fertility desires and intentions; the interview
was repeated at 6 months and annually thereafter. Women
provided written informed consent for interview, and were
part of the ongoing Rakai community cohort surveillance
(RCCS). The RCCS study was approved by the Science
and and Ethics Committee of the Uganda Virus Research
Institute, the Ugandan National Council for Science and
Technology, and the Western Institutional Review Board.
2.2. Deﬁnition of Key Variables. Pregnancy was detected
through self-report and hCG urine test for those uncertain
of their pregnancy status or whose last normal menstrual
period (LNMP) was more than 30 days prior to interview,
with the exception of women using Depo-Provera or
norplant, and those who were postmenopausal or had
lactational amenorrhoea <2 months, who were excluded
from this analysis. Prevalent pregnancies were deﬁned as
thosedetectedatorwithintwo-weeksofenrolmentintoHIV
care or ART initiation. Incident pregnancies were deﬁned as
those ﬁrst detected more than 2 weeks after entry in HIV
care or ART initiation. (The two-week window was included
because,onaverage,usingthepregnancykitsavailabletothis
program, hcg could only be detected in a pregnant woman’s
urine after at least 10 days.) If a woman had more than
one pregnancy during follow-up, only the ﬁrst pregnancy
was considered for the incidence analysis, and subsequent
observation time was censored.
All women initiating ART had CD4 counts of ≤250
cells/mm3 and were categorized into CD4 counts <100 or
100–250cells/mm3.Desireformorechildrenwascategorized
as both partners wanting a child, only the male or the female
partner wanting a child, or neither wanting a child.
We also grouped responses to desire for more children
into four categories as (i) both partners did not want a child if
neither wanted more children, (ii) only male partner wanted
a child, (iii) only the woman wanted more children, (iv) both
wanted (more) children.
2.3. Statistical Analysis. T h et w ok e yo u t c o m e sf o rt h i s
analysis were prevalent pregnancy deﬁned as a pregnancy at
enrolment into HIV care for the pre-ART period, or at ART
initiation or within the ﬁrst 2 week of follow-up for those
initiated on ART. Incident pregnancy was deﬁned as the ﬁrst
pregnancy during subsequent visits starting at the 2nd week
followupfollowing ARTinitiation andat 3 or6 months visits
after enrolment in HIV care prior to ART initiation, among
women who were not pregnant at time of enrollment in care
or initiation of ART.
2.3.1. Analyses of Incident Pregnancy during HIV Care prior
to ART and during ART. The prevalence of pregnancy at
two time points (at the time of HIV care initiation and at
ART initiation) was determined as the number of women
pregnant at time of HIV care or ART initiation divided by
the total number of sexually active women of childbearing
age (15–45 years) starting HIV care or ART (premenarche
women and women using depo-provera or norplant, and
those who were post menopausal or had lactational amenor-
rhoea <2 months were excluded from analysis). Prevalence
risk ratios (PRR) and 95% conﬁdence intervals (CI) were
estimated using generalized linear models (glm) with family
of binomial and log link. Models for adjusted PRR included
baseline CD4 and other factors statistically signiﬁcant at p<
0.15 in univariate analyses or potential confounders.
The incidence of new pregnancies detected between the
second week up to the 48th week during two time periods
(after initiation of HIV care and after initiation of ART) was
estimated as the number of ﬁrst pregnancies in each time
period divided by the total person-years (py) accrued in that
time period before pregnancy detection or before censoring
at week 48. Incidence rate ratios (IRR) of ﬁrst pregnancy andAIDS Research and Treatment 3
95% conﬁdence intervals (CI) were estimated using Poisson
regression with observation time as an oﬀset.
Covariates assessed in the pre-ART period pregnancy
incidence included CD4 at screening for enrolment into
HIV care, categorized as 251–350 and 351+ cells/mm3,
age at enrolment, marital status, family planning use, and
breastfeedinginthepast12months.Inmultivariablemodels,
we adjusted for factors statistically signiﬁcant at p<0.15
or potential confounders. The main factor of interest in this
analysis was CD4 counts at enrolment into HIV care.
For the ART treatment period, covariates included
change in CD4 counts between baseline (the time of ART
initiation) and week 12 of treatment, divided into three
categories: baseline and week 12 CD4 were both <100
cells/mm3, baseline CD4 was <100, week 12 CD4 was 100+
cells/mm3 and both baseline CD4 and week 12 were 100+
cells/mm3, age at ART initiation, marital status, baseline
desire for children, body mass index (BMI) calculated as
(Weight in Kilograms/(Height in Meters) × (Height in
Meters)) at week 12, family planning use at baseline, and
HIV viral load at week 24. In multivariable models, we
adjusted for factors which were statistically signiﬁcant at
p<0.15 in univariate analyses or potential confounders.
Using Kaplan-Meier survival curves, we also assessed the
association between CD4 counts and the cumulative prob-
abilities of incident pregnancies comparing women in the
threecategoriesofchangeinCD4betweenbaseline andweek
12. The log-rank test was used to assess diﬀerences in the
cumulative probabilities of pregnancy between these CD4
change categories.
In both, the generalized linear models (glm), for esti-
mation of the PRR and IRR, we adjusted for clustering
of observation at the mobile clinic (hub) levels, because
women attending speciﬁc mobile clinics were more likely
to be similar in various characteristics than those attending
others.
3. Results
Table 1 showsthecharacteristicsofwomenwhoenrolledinto
pre-ART HIV care in the RHSP. The majority were aged 25–
34 years (54.8%), currently married (48.2%), and those with
no sexual partners in the past 6 months (64.4%). About 40%
had parity of 4 or more children, and 37% were prime gravi-
dae. About 18.4% used medications to prevent pregnancies,
but injectables were the most commonly reported pregnancy
prevention medication among users 187/278 (67%). Among
those with available data on measures of health indicators,
about 10% had been bedridden in the past 30 days, 20.4%
withWHOstageof3/4,andaboutathird(32%)wereeligible
forARTinitiationbyCD4countof ≤250cells/mm3asperthe
RHSP criteria.
3.1. Prevalence and Incidence of Pregnancy during HIV Care
prior to ART. Table 2 shows the prevalence and prevalence
risk ratios of pregnancy among HIV+ women at enrollment
into HIV care prior to ART. The prevalence of pregnancy
at enrolment into HIV care was 7.2% (109/1514). Factors
signiﬁcantly associated with higher prevalence of pregnancy
were CD4 >350 cells/mm3 (adj. PRR = 4.71; 95% CI 1.41,
15.80), being currently married (adj. PRR = 3.82; 95%
CI 1.83, 7.97). Factors associated with lower pregnancy
prevalence were older age 25–34 years (adj. PRR = 0.55;
95% CI 0.34, 0.88) or 35–45 years (adj. PRR = 0.31; 95%
CI 0.15, 0.67) compared to women aged 15–24 years, those
breastfeeding in the past 12 month (adj. PRR = 0.16; 95% CI
0.08, 0.30), or those using medication to prevent pregnancy
(use of family planning) in the past 12 month (adj. PRR =
0.09; 95% CI 0.02, 0.33).
Table 3 shows the incidence of pregnancy and inci-
dence rate ratio of pregnancy prior to ART. The overall
incidence of pregnancy during the ﬁrst year in HIV care
was 13.1/100py, 95% CI (10.14, 16.75). Being currently
married as compared to never married tended to have
higher incidence of pregnancy, but this did not reach
statistical signiﬁcance, adj. IRR = 5.90 (0.87, 40.04) nor
was being divorced/separated/widowed. On the other hand,
the incidence of pregnancy was signiﬁcantly reduced among
women reporting use of medication to prevent pregnancy
(nonuse of family planning) in past 12 months, adj. IRR =
0.22 (0.08, 0.61), older age (35–45 years) compared to young
age (15–24 years), adj. IRR = 0.15 (0.07, 0.34), and parity
of 1–3 children compared to prime gravids, adj. IRR = 0.43
(0.22, 0.86). The level of CD4 counts at entry into HIV care
prior to ART initiation was not associated with incidence of
pregnancy 13.2.0/100py 95% CI (10.02,17.23) for the 351+
cells/mm3 compared to 12.4/100py 95% CI (5.68,23.60) for
the 251–350 cells/mm3.
3.2. Prevalence and Incidence of Pregnancy during ART Use.
Table 4 shows the prevalence of pregnancy and the preva-
lence rate ratios at the time of ART initiation. The prevalence
of pregnancy was 10.1% (7.7, 12.9). The prevalence of preg-
nancy was higher among women with baseline CD4 of 100–
250 (12.0%), compared to those with CD4 <100 (3.2%, adj.
PRR = 3.24; 95% CI 1.51, 6.93). Also, the prevalence of preg-
nancy was signiﬁcantly associated with desire for more chil-
drenespeciallywhenboththewomanandherspousedesired
a (more) child compared to women in which both partners
did not want a (more) child (adj. PRR = 2.27; 95% CI 1.04,
4.97), among currently married women (adj. PRR = 1.33;
95%CI1.00,1.76)comparedtothosenotinunion,andolder
women aged 35–45 years compared to the younger women
aged 15–24 years (adj. PRR = 0.47; 95% CI 0.25, 0.91).
Among the 566 women with data at the time of ART
initiation, the overall mean (SD) CD4 counts were 159.0
cells/mm3 (SD = 72.7). The CD4 counts were signiﬁ-
cantly higher among the 57 pregnant women 184.0 (57.5)
cells/mm3 compared to the 509 nonpregnant women (156.2
cells/mm3, p = 0.0013). Among the pregnant women, 24.6%
(14/57) reported that only the male spouse desired to have
a (another) child compared to 1.8% (1/57), where only the
female did (p = 0.0003).
A total of 244 women were eligible for the analysis of
incident pregnancy after ART initiation. The incidence of
pregnancy was 24.6/100py; 95% CI 18.1, 32.6. The incidence
tended to be higher among women whose CD4 counts at the
time of ART initiation were either higher than 100 cells/mm34 AIDS Research and Treatment
Table 1: Characteristics of women enrolling into pre-ART HIV care.
Characteristics Number of women∗ Proportion, %
Overall 1514 100
Age (years)
15–24 199 13.1
25–34 830 54.8
35–45 485 32.0
Marital status
Never married 155 10.2
Divorced/separated/widowed 629 41.6
Currently married 730 48.2
Sexual partner past 6 months
None 970 64.4
One 493 32.7
2+ 43 2.9
Fertility and family planning
Pregnancy status
Not pregnant 1405 92.8
Pregnant 109 7.2
Parity (ever live-births)
Prime gravid 545 36.9
1–3 353 23.9
4+ 580 39.2
Use of any medication to prevent pregnancy
Not taking any 1236 81.6
Taking some medications 278 18.4
Medications used to prevent pregnancy
Not taking any 1236 81.7
Injectables 187 12.4
Tablets 56 3.7
Others 34 2.3
Breastfeeding
Not breastfeeding 1286 84.9
Yes breastfeeding 228 15.1
General health
Bed-ridden in past 30 days
No 473 89.8
Yes 54 10.3
WHO stage at initial screening
I 476 48.3
II 309 31.3
III 151 15.3
IV 50 5.1
CD4 at initial screening
<100 167 11.0
100–250 312 20.6
251–350 173 11.4
351+ 862 56.9
Note ∗some totals do not add up to 1514 because of missing information on variables.AIDS Research and Treatment 5
Table 2: Prevalence of pregnancy, unadjusted and adjusted prevalence risk ratios among HIV+ women prior to ART initiation.
Characteristics Unadjusted Adjusted
Pregnant/total (%) PRR (95% CI) PRR (95% CI)
Overall 109/1514 (7.2)
Age (years)
15–24 31/199 (15.6) 1.0 1.0
25–34 61/830 (7.4) 0.47 (0.30, 0.74) 0.55 (0.34, 0.88)
35–45 17/485 (3.5) 0.23 (0.11, 0.47) 0.31 (0.15, 0.67)
Marital status
Never married 5/155 (3.2) 1.0 1.0
Divorced/separated/widowed 15/629 (2.4) 0.74 (0.27, 2.5) 0.80 (0.28, 2.22)
Currently married 89/730 (12.2) 3.78 (1.81, 7.90) 3.82 (1.83, 7.97)
Sexual partner past 6 months
None 63/970 (6.5) 1.0
One 44/493 (8.9) 1.37 (0.92, 2.04)
2+ 2/43 (4.7) 0.72 (0.17, 3.07)
Parity (ever live-births)
Prime gravid 41/545 (7.5) 1.0
1–3 26/353 (7.4) 0.98 (0.57, 1.67)
4+ 41/580 (7.1) 0.94 (0.64, 1.38)
Use of any medication to prevent pregnancy
Not taking any 106/1236 (8.6) 1.0 1.0
Taking some medications 3/278 (1.1) 0.13 (0.03, 0.47) 0.09 (0.02, 0.33)
Breastfeeding
Not breastfeeding 103/1286 (8.0) 1.0 1.0
Yes breastfeeding 6/228 (2.6) 0.33 (0.17, 0.64) 0.16 (0.08, 0.30)
WHO stage at initial screening
I 46/476 (9.7) 1.0
II 14/309 (4.5) 0.47 (0.26, 0.84)
III 4/151 (2.7) 0.27 (0.13, 0.58)
IV 5/40 (10.0) 1.03 (0.53, 2.00)
CD4 at initial screening
<100 3/167 (1.8) 1.0 1.0
100–250 16/312 (5.1) 2.85 (0.89, 9.13) 2.74 (0.85, 8.82)
251–350 9/173 (5.2) 2.90 (0.95, 8.83) 2.22 (0.71, 6.98)
351+ 81/862 (9.4) 5.23 (1.54, 17.74) 4.71 (1.41, 15.80)
or were improved beyond 100 cells/mm3 by week 12
post-ART initiation (Table 5). Factors associated with high
incidence of pregnancy but which did not reach statistical
signiﬁcanceinclude being currentlymarried whencompared
to never married (adj. IRR = 1.41; 95% CI 0.76, 2.59) and
CD4 counts of 100 or higher by week 12 while on ART.
Older age 35–45 years was signiﬁcantly associated with lower
incidence of pregnancy (adj. IRR = 0.27; 95% CI 0.15, 0.50).
Pregnancy incidence tended to increase when both women
and their spouses desired more children, but this increase
was not signiﬁcant (adj. IRR = 1.07; 95% CI 0.43, 2.63). If
only the woman wanted (more) children, the incidence of
pregnancy tended to be lower (adj. IRR = 0.50; 95% CI 0.09,
2.81) compared to when both partners did not want (more)
children. The ﬁrst viral load suppression data were available
at week 24 after initiating ART. Although women with
undetectable viral load had higher pregnancy rates, this was
not signiﬁcantly diﬀerent from women with detectable viral
loads, adj. IRR = 1.52; 95% CI (0.72; 3.22; results not shown
inTable 5).Useoffamilyplanning methods, BMIatweek12,
and WHO stage at week 12 were not associated with incident
pregnancy. Figure 1 shows the Kaplan-Meier cumulative
probability of incident pregnancy in the ﬁrst 48 weeks
while on ART treatment, by CD4 counts level at week 12.
The cumulative probability of incident pregnancy increased
overtime and was higher among women with CD4 count
≥100+ compared to those with CD4 counts level of less
than 100 cells/mm3, but this diﬀerence was not statistically
signiﬁcant(logrankχ2 = 2.32; p = 0.3133).Theincidenceof
pregnancy prior to ART 13.1/100py was signiﬁcantly lower
comparedtoincidenceafterARTinitiation,24.6/100py(IRR
= 0.54, 95% CI 0.37, 0.81, p<0.0017).6 AIDS Research and Treatment
Table 3: Incidence of pregnancy, unadjusted and adjusted incidence rate ratios among HIV+ women prior to ART initiation.
Characteristics Number of
women
Incident
pregnancy/pyrs
Incidence/100 pyrs
(95% CI) IRR (95% CI) Adjusted IRR
(95% CI)
Overall 712 65/494.6 13.1 (10.14, 16.75)
CD4 at screening
251–350 130 9/72.4 12.4 (5.68, 23.60) 1.0 1.0
351+ 582 56/422.1 13.2 (10.02, 17.23) 1.07 (0.57, 2.01) 0.95 (0.44,
2.05)
Age (years)
15–24 84 14/54.5 25.7 (14.0, 43.31) 1.0 1.0
25–34 389 44/268.4 16.4 (11.91, 22.00) 0.64 (0.36, 1.12) 0.73 (0.45,
1.19)
35–45 239 7/171.7 3.5 (1.28, 7.60) 0.16 (0.06,0.40) 0.15(0.07,
0.34)
Marital status
Never married 60 2/40.1 5.0 (0.60, 18.03) 1.0 1.0
Divorced/separated/widowed 310 20/217.2 9.2 (5.62, 14.22) 1.84 (0.45, 7.53) 3.83 (0.55,
26.77)
Currently married 342 43/237.2 18.1 (13.12, 24, 42) 3.62 (0.84, 15.74) 5.90 (0.87,
40.04)
Use of any medication to prevent
pregnancy
Not taking any 485 57/325.8 17.5 (13.25, 22.67) 1.0 1.0
Taking some medications 227 8/168.8 4.7 (2.05, 9.34) 0.27 (0.10,0.73) 0.22(0.08,
0.61)
Breastfeeding
Not breastfeeding 572 49/397.9 12.3 (9.11, 16.28) 1.0 1.0
Yes breastfeeding 140 16/96.7 16.5(9.46, 26.87) 1.34 (0.95, 1.89) 0.43 (0.48,
1.06)
Parity (ever live-births)
Prime gravid 301 38/211.1 18.0 (12.74, 24.71) 1.0 1.0
1–3 134 8/93.1 8.4 (3.71, 16.93) 0.48 (0.27,0.83) 0.43(0.22,
0.86)
4+ 267 18/184.5 9.8 (5.78, 15.42) 0.54 (0.30,0.99) 0.73(0.39,
1.36)
WHO stage at initial screening
I 249 20/174.5 11.5 (7.00, 17.70) 1.0
II 133 7/90.6 7.7 (3.11, 15.92) 0.67 (0.28, 1.62)
III/IV 35 1/22.5 4.4 (0.11, 24.76) 0.39 (0.06, 2.56)
4. Discussion
We found that the incidence of pregnancy was lower prior
to initiation of ART and signiﬁcantly increased while on
ART. Pregnancy prevalence was signiﬁcantly reduced with
lower CD4 counts and tended to increase among women
with viral suppression and good CD4 cell response while
on ART. The incidence of pregnancy also tended to increase
when both women and their spouses desired more children
and decreased with older age. These ﬁndings are consistent
withother studies which showed increased fertility afterART
initiation [21, 22].
The signiﬁcantly higher incidence of pregnancy after
initiating ART compared to prior to ART could be due to
improved immune status or reduced HIV viral load. An eth-
nologicstudyinNigeriashowedthatimprovementsinhealth
status after initiating ART enabled women to reassess their
childbearing [24], while in another study people living with
HIV (PLHIV) viewed having children as making them look
forward to the future thus providing them a reason to live [1,
25]. Such views are important to be integrated in reproduc-
tivehealthservicecomponentsoftheARTprogramsasaway
of empowering women to make appropriate reproductive
health decisions. Previous studies suggest that women on
HAART are signiﬁcantly more likely to use contracep-
tives [25–27], but treatment optimism aﬀects their fertility
intentions [28–30]. In Rakai, the provision of Prevention
of Mother to Child Transmission (PMTCT) interventions,AIDS Research and Treatment 7
Table 4: Prevalence of pregnancy, unadjusted and adjusted PRR among HIV women at time of initiating ART.
Characteristics Unadjusted Adjusted
Pregnant/total (%) PRR (95% CI) PRR (95% CI)
Overall 57/566(10.1)
Baseline CD4
<100 4/124 (3.2) 1.0 1.0
100–250 53/442 (12.0) 3.72 (1.37, 10.08) 3.24(1.51, 6.93)
Age
15–24 8/46 (17.4) 1.0 1.0
25–34 35/304 (11.5) 0.66 (0.34, 1.34) 0.73 (0.39, 1.34)
35–45 14/216 (6.5) 0.37 (0.17, 0.84) 0.47(0.25, 0.91)
Desire for more children
Both do not want 28/387 (7.2) 1.0 1.0
Only male partner wants 14/102 (13.7) 1.90 (1.04, 3.47) 1.54(0.81, 2.94)
Only female wants 1/18 (5.6) 0.77 (0.11, 5.34) 0.78 (0.10, 5.90)
Both want 14/59 (23.7) 3.28 (1.84, 5.86) 2.27(1.04, 4.97)
Marital status
Not in union 22/308 (7.1) 1.0 1.0
In union 35/258 (13.6) 1.90 (1.14,3.15) 1.33(1.00, 1.76)
HIV status disclosure
Not to anybody 5/98 (5.1) 1.0 1.0
Yes, to somebody 52/468 (11.1) 2.18 (0.89,5.31) 1.86 (0.87, 3.99)
∗FP use at ART initiation
None 52/452 (11.5)
Only condoms 0/8 (0)
Other methods 0/7 (0)
∗Total less than 566 because some do not have data available.
0
C
u
m
u
l
a
t
i
v
e
p
r
o
b
a
b
i
l
i
t
y
o
f
b
e
c
o
m
i
n
g
p
r
e
g
n
a
n
t
0.1
0.2
0.3
0.4
0.5
0369 1 2
log-rank χ2 = 2.32,P = .3133
Base and wk12 = 100 + both
Base and wk12 CD4 = improved <100 to 100+
Base and wk12 CD4 = <100, no change
Time since ART initiation (months)
Figure 1: Probability of pregnancy while on ART among women,
15–45 years.
including infant formula to HIV-exposed babies, might also
have aﬀected HIV+ women fertility intentions.
Desire for (more) children, being currently married, and
younger age are known to be associated with increased preg-
nancy. A recent study in Kenya has shown that HIV/AIDS
patients have increased the desire for children and increased
fertility partly due to increased infant/child mortality and
reduced breastfeeding [31]. Social expectations are also
associated with increased desire for more children [28], and
ART is associated with higher fertility desires and intentions
[28–30]. In our study, a signiﬁcantly higher proportion of
women reported that their spouses desired more children
compared to the women. This ﬁnding was consistent with
previous studies in various cultural settings [32, 33]. Men’s
higherdesirefor(more)childrenortheirfuturereproductive
intentions may partly be explained by their knowledge about
the positive eﬀects of PMTCT on infant health [1]. This
ﬁnding suggests that reproductive health services, especially
educative health messages about reproductive issues, should
also be extended to involve men rather than focusing only on
the needs of the female.
In summary, our data and ﬁndings from other previous
studies [21, 22] show that women’s fertility increases while
on ART either as a result of their improved health and
well-being leading to a reevaluation of their intentions and
decisions regarding childbearing, or through improvement
of their immunological and virological outcomes that may
increase the probability of conception. Therefore, ART
programs need to broaden their counseling on reproductive
health services to follow the WHO (2006) Guidelines on
care, treatment and support for women living with HIV/AIDS
and their children in resource-constrained settings which
recommend that the selection of ART regimen for women
should consider the possibility of a planned or unintended
pregnancy.
Women in the ART programs need to be equipped with
information on eﬀective contraceptive methods to prevent8 AIDS Research and Treatment
Table 5: Incidence of pregnancy, unadjusted and adjusted IRR among HIV+ women after initiating ART.
Characteristics Number of
women
Incident
pregnancy/pyrs
Incidence/100 pyrs
(95% CI) IRR (95% CI) Adjusted IRR
(95% CI)
Overall 244 48/195.5 24.6 (18.1, 32.6)
Baseline and week 12 CD4
Both <100 18 1/14.69 6.8 (0.17, 37.92) 1.0 1.0
Both 100+ 182 39/145.50 26.8 (19.06, 36.64) 3.94 (0.68, 22.70) 4.12 (0.75,
22.50)
Base CD4 <100, wk12
100+ 44 8/35.38 22.6 (9.76, 44.55) 3.32 (0.50, 2.26) 3.24 (0.46,
22.60)
Age (years)
15–24 19 6/14.31 41.9 (15.39, 91.26) 1.0 1.0
25–34 133 34/103.94 32.7 (22.65, 45.71) 0.78 (0.44, 1.39) 0.82 (0.38,
1.77)
35–45 92 8/77.31 10.3 (4.47, 20.39) 0.25(0.13, 0.46) 0.27(0.15,
0.50)
Desire for more children
Both do not want 179 34/144.52 23.5 (16.29, 32.88) 1.0 1.0
Only male wants 35 6/28.88 20.8 (7.62, 45.23) 0.88 (0.33, 2.33) 0.81 (0.36,
1.84)
Only female wants 8 1/6.13 16.3 (0.41, 90.89) 0.69 (0.12, 4.12) 0.50 (0.09,
2.81)
Both want 22 7/16.04 43.6 (17.55, 89.92) 1.85 (0.84, 4.10) 1.07 (0.43,
2.63)
Marital status
Not married 142 23/117.13 19.6 (12.45, 29.46) 1.0 1.0
Married 102 25/78.44 31.9 (20.63, 47.05) 1.62 (0.81, 3.25) 1.41 (0.76,
2.59)
HIV status disclosure
Not to anybody 58 15/45.69 32.8 (18.37, 54.15) 1.0 1.0
Yes, to somebody 186 33/149.88 22.0 (15.16, 30.92) 0.67 (0.38, 1.19) 0.69 (0.36,
1.32)
∗Family planning method
None 69 18/51.83 34.7 (20.58, 54.89) 1.0
Condom only 45 12/35.45 33.8 (17.49, 59.13) 0.97 (0.47, 2.00)
Other 11 2/8.34 24.0 (2.91, 86.67) 0.69 (0.16, 3.08)
∗BMI at week 12
Under weight, <18.5 24 5/18.11 5 (8.96, 64.43) 1.0
Normal weight 139 28/113.83 24.5 (16.35, 35.55) 0.89 (0.29, 2.72)
Overweight/obese 33 5/27.23 18.4 (5.96, 42.85) 0.67 (0.14, 3.16)
∗WHO stage at week 12
I & II 94 19/75.81 25.1 (15.09, 39.14) 1.0
III & IV 48 6/39.27 15.3 (5.61, 33.26) 0.61 (0.23, 1.63)
∗Data not available on all the 244 women.
pregnancy, if so desired, as well as information on the
potential drug interactions with hormonal contraceptives to
enable them make informed decisions on childbearing.
The other potential program/policy challenge is that
pregnancy is an indicator of engagement in unprotected sex.
If women and their spouses still desire to have a (another)
child they will have unprotected sex, which can result in
increased risk of HIV transmission to sexual partners, in
addition to acquisition of multiple HIV virus strains to the
already infected woman on ART. Such scenarios can lead to
failure on ﬁrst-line regimen further exposing the women to
increased risk of morbidity and mortality.
On the other hand, ART programs that are providing
or advising women to use hormonal contraceptives should
provide information on the potential risk of interaction
between ARVs and some hormonal contraceptives [34]
which alter the safety and eﬀectiveness of both the hor-
monal contraceptives and the antiretroviral drugs. Also ARTAIDS Research and Treatment 9
programs need to be aware of the potential risk of pill
burden of both ARV drugs and contraceptives that may
compromise adherence to the contraceptives or the HIV-
related medication if method of contraceptive choice is pills.
Therefore, ART programs should fully engage women
and their partners whenever possible, to make them aware of
such considerations while selecting contraceptive methods
if they desire to use them, or the potential consequences of
having unprotected sex if they still desire to have a (another)
child. Full reproductive health services integration into HIV
care program including family planning as well as health
e d u c a t i o ns h o u l di n v o l v eb o t hm e na n dw o m e nt oh e l p
them make informed decisions on their reproductive and
sexuality needs.
This study had limitations especially in the depth and
scope of data that could be used to address some key issues.
For example, detailed data on socioeconomic status as well
as contraceptive methods and history of child bearing were
not collected at the time of enrolling in HIV care. Also, the
available sample size for this analysis was limited resulting in
wide conﬁdence intervals for measures of association used.
However, our ﬁndings are still consistent with results from
other larger studies addressing the incidence pregnancy and
enrolment into ART programs.
5. Conclusion
In conclusion, fertility is increased among HIV-infected
women after initiation of ART, and the desire by both men
and women to have (more) children is still high reinforcing
the need for increased reproductive health services includ-
ing family planning as well as educative health messages
to enable HIV-infected women and their spouses make
informed decisions about their reproductive and sexuality
needs.
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